(n){if(!window.cnxel){window.cnxel={},window.cnxel.cmd=[];var t=n.createElement('iframe');t.src='javascript:false'; t.display='none',t.onload=function(){var ...

Civica will begin selling a type of insulin on Jan. 1, 2026, although it will not come from the nonprofit drug maker’s ...

New York, United States , June 12, 2024 (GLOBE NEWSWIRE) -- The Global Insulin Glargine Market Size is to Grow from USD 1.38 Billion in 2023 to USD 2.50 Billion by 2033, at a Compound Annual Growth ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...

California will begin offering its own brand of low-cost insulin in 2026, becoming the first state to contract for and sell ...

Among 475 patients randomized in a 1:1:1:1 fashion, those on one of three doses of injectable tirzepatide -- 5 mg, 10 mg, or 15 mg -- in addition to insulin glargine saw a significantly greater mean ...

The authors say there has been a recent uptick in hosptial admissions from hypoglycemic events, and that a therapy to address this is needed. A review of 15 studies has found that insulin degludec, ...

HAMBURG, Germany ― Once-weekly tirzepatide (Mounjaro, Lilly) added to insulin glargine resulted in greater reductions in A1c along with more weight loss and less hypoglycemia compared with prandial ...

In this study, we examined the pharmacokinetic and pharmacodynamic dose-response effects of single subcutaneous injections of insulin glargine in obese type 2 diabetic individuals. Our study ...

Luton, Bedfordshire, United Kingdom, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...